GLP-1 and Your Heart: More Than Weight Loss
GLP-1 medicines are best known for weight loss, but a growing body of evidence points to real benefits for the heart. In the landmark SELECT trial, semaglutide (the ingredient in Wegovy and Ozempic) reduced the risk of major cardiovascular events - such as heart attack and stroke - by about 20% in adults with obesity and established heart disease who did not have diabetes. That result helped shift how doctors think about these drugs.
How can a weight-loss drug protect the heart? Part of it is the weight loss itself, which eases blood pressure, blood sugar, and strain on the heart. But researchers believe there are also more direct effects, including lower inflammation and improvements in how blood vessels work. Based on this evidence, the FDA approved Wegovy to reduce cardiovascular risk in certain adults - a use that goes beyond weight alone.
What does this mean for you? If you carry extra weight and already have heart disease or a high risk of it, a GLP-1 medicine may offer a double benefit: helping with weight and lowering cardiovascular risk. But these drugs are not right for everyone, they have side effects, and they do not replace other heart medicines your doctor may have prescribed, such as statins or blood-pressure treatment.
The takeaway is that GLP-1 therapy is becoming part of a bigger picture of metabolic and heart health, not just a number on the scale. If you have heart concerns or risk factors, ask your doctor about your full risk profile and whether one of these medicines fits your overall plan. This is general information, not medical advice.